Metformin attenuates ventricular hypertrophy by activating the AMP‐activated protein kinase–endothelial nitric oxide synthase pathway in rats
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Summary: 1. Metformin is an activator of AMP‐activated protein kinase (AMPK). Recent studies suggest that pharmacological activation of AMPK inhibits cardiac hypertrophy. In the present study, we examined whether long‐term treatment with metformin could attenuate ventricular hypertrophy in a rat model. The potential involvement of nitric oxide (NO) in the effects of metformin was also investigated. 2. Ventricular hypertrophy was established in rats by transaortic constriction (TAC). Starting 1 week after the TAC procedure, rats were treated with metformin (300 mg/kg per day, p.o.), NG‐nitro‐l‐arginine methyl ester (l‐NAME; 50 mg/kg per day, p.o.) or both for 8 weeks prior to the assessment of haemodynamic function and cardiac hypertrophy. 3. Cultured cardiomyocytes were used to examine the effects of metformin on the AMPK–endothelial NO synthase (eNOS) pathway. Cells were exposed to angiotensin (Ang) II (10−6 mol/L) for 24 h under serum‐free conditions in the presence or absence of metformin (10−3 mol/L), compound C (10−6 mol/L), l‐NAME (10−6 mol/L) or their combination. The rate of incorporation of [3 H]‐leucine was determined, western blotting analyses of AMPK–eNOS, neuronal nitric oxide synthase (nNOS) and inducible nitric oxide synthase (iNOS) were undertaken and the concentration of NO in culture media was determined. 4. Transaortic constriction resulted in significant haemodynamic dysfunction and ventricular hypertrophy. Myocardial fibrosis was also evident. Treatment with metformin improved haemodynamic function and significantly attenuated ventricular hypertrophy. Most of the effects of metformin were abolished by concomitant l‐NAME treatment. l‐NAME on its own had no effect on haemodynamic function and ventricular hypertrophy in TAC rats. 5. In cardiomyocytes, metformin inhibited AngII‐induced protein synthesis, an effect that was suppressed by the AMPK inhibitor compound C or the eNOS inhibitor l‐NAME. The improvement in cardiac structure and function following metformin treatment was associated with enhanced phosphorylation of AMPK and eNOS and increased NO production. 6. The findings of the present study indicate that long‐term treatment with metformin could attenuate ventricular hypertrophy induced by pressure overload via activation of AMPK and a downstream signalling pathway involving eNOS–NO.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tzoulaki, I., Molokhia, M., Curcin, V., Little, M. P., Millett, C. J., Ng, A., Hughes, R. I., Khunti, K., Wilkins, M. R., Majeed, A., et al. (2009) · BMJ · doi:10.1136/bmj.b4731 · Cited by 444 · cited 2×
“Clinical observations suggest that metformin is cardioprotective via a mechanism(s) independent of its blood glucose-lowering action.(7,8) Recent studies suggest that AMPK activity is increased during the development of cardiac hypertrophy.”
BackgroundCalvert, J. W., Gundewar, S., Jha, S., Greer, J. J. M., Bestermann, W. H., Tian, R., & Lefer, D. J. (2008) · Diabetes · doi:10.2337/db07-1098 · Cited by 422
Chan, A. Y. M., Soltys, C.-L. M., Young, M. E., Proud, C. G., & Dyck, J. R. B. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m403528200 · Cited by 331
Metformin therapy and clinical uses
Scarpello, J. H., & Howlett, H. C. (2008) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2008.027 · Cited by 318 · cited 3×
“It is widely believed that a variety of effects of metformin, includ- ing antidiabetic effects, are mediated by the activation of AMPK.1,2,5,6 The present study demonstrated that metformin enhances AMPK phosphorylation.”
Background
Cited by
Cellular and molecular mechanisms of metformin: an overview
Viollet, B., Guigas, B., Garcia, N. S., Leclerc, J., Foretz, M., & Andreelli, F. (2012) · Clinical Science · doi:10.1042/cs20110386 · Cited by 1,720
The intersection between aging and cardiovascular disease
North, B. J., & Sinclair, D. A. (2012) · Circulation Research · doi:10.1161/circresaha.111.246876 · Cited by 1,585
Metformin: from mechanisms of action to therapies
Foretz, M., Guigas, B., Bertrand, L., Pollak, M., & Viollet, B. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.09.018 · Cited by 1,501
Kenny, H. C., & Abel, E. D. (2019) · Circulation Research · doi:10.1161/circresaha.118.311371 · Cited by 660
Nesti, L., & Natali, A. (2017) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2017.04.009 · Cited by 211
Metadata
- Authors
- Zhang, C., Pan, S., Meng, R., Peng, C., Xiong, Z., Chen, B., Chen, G., Yao, F., Chen, Y., Ma, Y., & Dong, Y.
- Venue
- Clinical and Experimental Pharmacology and Physiology
- Publisher
- Wiley
- Published
- 2010-12-29
- Volume
- 38
- Issue
- 1
- Pages
- 55-62
- ISSN
- 0305-1870 (ISSN-L)
- 1440-1681
- OpenAlex
- W2127322520
- Cited by
- 91
- References
- 4
- FWCI
- 0.95
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Metformin attenuates ventricular hypertrophy by activating the AMP‐activated protein kinase–endothelial nitric oxide synthase pathway in rats. https://app.cochat.ai/papers/10.1111/j.1440-1681.2010.05461.x
- The paper
- Zhang, C., Pan, S., Meng, R., Peng, C., Xiong, Z., Chen, B., Chen, G., Yao, F., Chen, Y., Ma, Y., & Dong, Y. (2011). Metformin attenuates ventricular hypertrophy by activating the AMP‐activated protein kinase–endothelial nitric oxide synthase pathway in rats. Clinical and Experimental Pharmacology and Physiology. https://doi.org/10.1111/j.1440-1681.2010.05461.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.